{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:00:58Z","timestamp":1782320458561,"version":"3.54.5"},"reference-count":48,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"unspecified","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,5,6]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of upadacitinib versus adalimumab through 7 years in the ongoing SELECT-COMPARE study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) were randomised to placebo, upadacitinib 15 mg once daily or adalimumab 40 mg every other week (on background MTX). Inadequate responders were rescued to the alternate therapy, with placebo recipients switching to upadacitinib by week 26. Patients completing 48 weeks were eligible to enter the 10-year extension. Safety was assessed as treatment-emergent adverse events (TEAEs); efficacy was analysed by randomised group (non-responder imputation [NRI]) or treatment sequence (as observed [AO]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Upadacitinib was generally well tolerated, displaying TEAE rates comparable to adalimumab, but numerically higher rates of herpes zoster, creatine phosphokinase elevation, non-melanoma skin cancer, lymphopenia and hepatic disorders. Responses with continuous upadacitinib or adalimumab were maintained through 372 weeks; week 372 Clinical Disease Activity Index remission (\u22642.8) and 28-joint Disease Activity Score based on C-reactive protein&lt;2.6 were achieved by 145\/230 (63.0%) and 178\/204 (83.2%) (AO)\/142\/651 (21.8%) and 172\/651 (26.4%) (NRI) of patients with upadacitinib versus 46\/86 (53.5%) and 59\/81 (72.8%) (AO)\/43\/327 (13.1%) and 55\/327 (16.8%) (NRI) with adalimumab. Initial non-responders\/incomplete responders benefited from switching, with improvements in efficacy endpoints maintained through week 336 post switch, without additional safety concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The safety profile of upadacitinib remained consistent with previous analyses, with no new safety concerns through 7 years. Upadacitinib and adalimumab (continuous or rescue treatment) maintained disease activity targets throughout the 7-year treatment period. Upadacitinib exhibited an acceptable benefit\u2013risk profile for long-term RA treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02629159\">NCT02629159<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006657","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:10:25Z","timestamp":1782317425000},"page":"e006657","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02629159","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"first","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas, USA"},{"name":"Metroplex Clinical Research Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Swierkot","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2356","authenticated-orcid":false,"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, UCLouvain Saint-Luc, P\u00f4le de Recherche en Rhumatologie, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Centre de recherche du CHU de Qu\u00e9bec, Laval University, Quebec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Hospital University Marqu\u00e9s de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duke","family":"Geem","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Luo","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren D","family":"Smith","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Caballero","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meerwein","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Peterfy","sequence":"additional","affiliation":[{"name":"Spire Sciences Inc, Boca Raton, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-0313","authenticated-orcid":false,"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Rheumatology, Organizaci\u00f3n Medica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026062409101377000_12.2.e006657.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.11.009"},{"key":"2026062409101377000_12.2.e006657.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8"},{"key":"2026062409101377000_12.2.e006657.3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"2026062409101377000_12.2.e006657.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00603-1"},{"key":"2026062409101377000_12.2.e006657.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab609"},{"key":"2026062409101377000_12.2.e006657.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224916"},{"key":"2026062409101377000_12.2.e006657.7","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/keae701","article-title":"Poor prognostic factors and unmet needs in rheumatoid arthritis","volume":"64","author":"Smolen","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026062409101377000_12.2.e006657.8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026062409101377000_12.2.e006657.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026062409101377000_12.2.e006657.10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003918","article-title":"Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"2026062409101377000_12.2.e006657.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2059-8","article-title":"Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026062409101377000_12.2.e006657.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01062-9"},{"key":"2026062409101377000_12.2.e006657.13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40744-024-00658-1","article-title":"Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE","volume":"11","author":"Fleischmann","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026062409101377000_12.2.e006657.14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026062409101377000_12.2.e006657.15","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212595","article-title":"Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis","volume":"8","author":"Biggioggero","year":"2019","journal-title":"Drugs Context"},{"key":"2026062409101377000_12.2.e006657.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2026062409101377000_12.2.e006657.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204317"},{"key":"2026062409101377000_12.2.e006657.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"2026062409101377000_12.2.e006657.19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"2026062409101377000_12.2.e006657.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2026062409101377000_12.2.e006657.21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2026062409101377000_12.2.e006657.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2026062409101377000_12.2.e006657.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2026062409101377000_12.2.e006657.24","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026062409101377000_12.2.e006657.25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004007","article-title":"Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"2026062409101377000_12.2.e006657.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218412"},{"key":"2026062409101377000_12.2.e006657.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764"},{"key":"2026062409101377000_12.2.e006657.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0334"},{"key":"2026062409101377000_12.2.e006657.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2026062409101377000_12.2.e006657.30","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026062409101377000_12.2.e006657.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2026062409101377000_12.2.e006657.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2026062409101377000_12.2.e006657.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80189-X"},{"key":"2026062409101377000_12.2.e006657.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"2026062409101377000_12.2.e006657.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"2026062409101377000_12.2.e006657.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2026062409101377000_12.2.e006657.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"2026062409101377000_12.2.e006657.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"2026062409101377000_12.2.e006657.39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2026062409101377000_12.2.e006657.40","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026062409101377000_12.2.e006657.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03565-0","article-title":"Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster","volume":"27","author":"Curtis","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026062409101377000_12.2.e006657.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916"},{"key":"2026062409101377000_12.2.e006657.43","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12030274","article-title":"Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases","volume":"12","author":"Yap","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026062409101377000_12.2.e006657.44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care &Amp; Research"},{"key":"2026062409101377000_12.2.e006657.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026062409101377000_12.2.e006657.46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005371","article-title":"Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease","volume":"11","author":"Burmester","year":"2025","journal-title":"RMD Open"},{"key":"2026062409101377000_12.2.e006657.47","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"key":"2026062409101377000_12.2.e006657.48","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:10:28Z","timestamp":1782317428000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006657"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006657","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}